Clinical Trial Update: Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642) [Phase 3]

View source ↗

Summary

Open-label extension of a Phase 3 study of denufosol tetrasodium inhalation solution in cystic fibrosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Denufosol Tetrasodium Inhalation Solution (denufosol tetrasodium)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cystic Fibrosis | Phase 3 | Status: TERMINATED